IMTX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Immatics NV

NASDAQ | IMTX

10.81

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$1.29B

Market Cap

-

P/E Ratio

-1.07

EPS

$11.25

52 Week High

$3.30

52 Week Low

HEALTHCARE

Sector

IMTX Chart

Recent Chart
Price Action

IMTX Technicals

Tags:

IMTX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit $156M
Total Revenue $156M
Cost Of Revenue $148M
Costof Goods And Services Sold $148M
Operating Income -$39M
Selling General And Administrative $46M
Research And Development $148M
Operating Expenses $194M
Investment Income Net -
Net Interest Income $24M
Interest Income $25M
Interest Expense $886K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $12M
Income Before Tax $21M
Income Tax Expense $6.1M
Interest And Debt Expense -
Net Income From Continuing Operations $15M
Comprehensive Income Net Of Tax -
Ebit $22M
Ebitda $34M
Net Income $15M

Revenue & Profitability

Earnings Performance

IMTX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (EUR)
Total Assets $696M
Total Current Assets $630M
Cash And Cash Equivalents At Carrying Value $237M
Cash And Short Term Investments $237M
Inventory -
Current Net Receivables $6.7M
Total Non Current Assets $67M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $1.6M
Intangible Assets Excluding Goodwill $1.6M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $368M
Other Current Assets $18M
Other Non Current Assets -
Total Liabilities $121M
Total Current Liabilities $68M
Current Accounts Payable $10M
Deferred Revenue -
Current Debt -
Short Term Debt $2.9M
Total Non Current Liabilities $53M
Capital Lease Obligations $16M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $16M
Other Current Liabilities $15M
Other Non Current Liabilities -
Total Shareholder Equity $575M
Treasury Stock -
Retained Earnings -$590M
Common Stock $1.2M
Common Stock Shares Outstanding $107M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (EUR)
Operating Cashflow -$158M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $12M
Capital Expenditures $16M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$152M
Cashflow From Financing $320M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $15M

yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit $156M
Total Revenue $156M
Cost Of Revenue $148M
Costof Goods And Services Sold $148M
Operating Income -$39M
Selling General And Administrative $46M
Research And Development $148M
Operating Expenses $194M
Investment Income Net -
Net Interest Income $24M
Interest Income $25M
Interest Expense $886K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $12M
Income Before Tax $21M
Income Tax Expense $6.1M
Interest And Debt Expense -
Net Income From Continuing Operations $15M
Comprehensive Income Net Of Tax -
Ebit $22M
Ebitda $34M
Net Income $15M

IMTX News

IMTX Profile

Immatics NV Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Immatics NV is a leading clinical-stage biopharmaceutical company headquartered in Tübingen, Germany, specializing in the development of T-cell receptor (TCR) based immunotherapies for various cancers. Leveraging its proprietary technology platforms, the company focuses on identifying and targeting distinct cancer-specific antigens to enhance immune responses against tumors. With a strong pipeline of innovative therapies aimed at addressing significant unmet medical needs in oncology, Immatics presents an appealing investment opportunity for institutional investors looking to support advancements in cancer treatment.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
KTTA
+54.72%
$1.64
VINE
+10.76%
$0.39
AMZE
+28.66%
$0.50
IPG
-1.95%
$24.57
TLRY
-20.11%
$0.82
NVDA
-1.76%
$177.08
AXDX
-61.36%
$0.03
YGMZ
-10.65%
$0.10
BITF
+11.80%
$3.46
ADAP
-15.14%
$0.05
INTC
+7.72%
$39.65
RUBI
-25.80%
$0.16
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
ASST
+2.65%
$1.16
RIG
+6.17%
$4.30
SRM
+53.27%
$10.30
BIYA
+11.30%
$0.28
AGNC
+1.53%
$10.56
BAC
+0.97%
$52.99
CLSK
+14.57%
$15.41
TWOH
0.00%
$0.00
INHD
-1.55%
$0.22
WLGS
-5.57%
$0.04
BMNR
+6.26%
$33.72
MTSR
-0.35%
$70.50
SNAP
+0.14%
$7.62
ONMD
+45.07%
$2.06
TSLA
+0.55%
$428.96
PCG
+1.78%
$16.01
CIFR
+10.05%
$21.07
PLUG
+2.09%
$2.02
AFMD
-34.94%
$0.18
ADTX
+18.78%
$3.72
MARA
+5.02%
$11.66
GPUS
-6.69%
$0.31
NVTS
+3.86%
$8.34
DEFT
+11.51%
$1.55
NIO
+0.36%
$5.48
KWM
+12.77%
$0.74
CHR
-4.18%
$0.04
BMNU
+14.89%
$8.64
F
+0.68%
$13.28
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
AMCR
+1.29%
$8.62
ONDS
-2.81%
$8.00
TEVA
+5.32%
$26.32
GOOGL
-0.60%
$318.02
SOFI
+3.18%
$29.39
VALE
+0.31%
$12.54
BTG
+3.37%
$4.62
CRCL
+11.05%
$80.67
KDLY
+7.20%
$0.49
AAL
+0.60%
$14.01
DVLT
-6.33%
$1.99
SMX
+222.58%
$56.13
CSCO
-0.32%
$76.07
IBRX
+11.50%
$2.37
CAN
+12.59%
$1.03
WULF
+5.18%
$15.61
IREN
-0.44%
$48.23
BTBT
+2.58%
$2.38
BURU
+5.44%
$0.23
SAND
-6.04%
$12.12
RIOT
+9.45%
$16.37
NGD
+5.86%
$8.30
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
APLD
+7.21%
$26.74
GRAB
+2.67%
$5.46
AG
+12.27%
$15.16
GOOG
-0.73%
$317.92
AMD
+0.97%
$216.32
CRCG
+21.27%
$2.85
KO
+0.37%
$72.88
C
+1.31%
$102.50
CRCA
+22.96%
$4.52
ABVE
+16.17%
$3.05
NEHC
+8.33%
$5.07
RIVN
+4.57%
$16.92
COMP
-0.76%
$10.42
CDE
+6.02%
$17.16
ACHR
+4.07%
$7.79
RF
+0.11%
$25.45
KEY
+0.16%
$18.40
MSTR
+2.73%
$180.44
DNN
+1.09%
$2.58
ZIM
+0.97%
$19.70
ORCL
-1.88%
$201.09
BTE
+2.68%
$3.24
AMC
+6.95%
$2.46
HL
+4.61%
$16.70
PLTR
+0.77%
$167.05
AMZN
+1.25%
$232.04
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
KTTA
+54.72%
$1.64
VINE
+10.76%
$0.39
AMZE
+28.66%
$0.50
IPG
-1.95%
$24.57
TLRY
-20.11%
$0.82
NVDA
-1.76%
$177.08
AXDX
-61.36%
$0.03
YGMZ
-10.65%
$0.10
BITF
+11.80%
$3.46
ADAP
-15.14%
$0.05
INTC
+7.72%
$39.65
RUBI
-25.80%
$0.16
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
ASST
+2.65%
$1.16
RIG
+6.17%
$4.30
SRM
+53.27%
$10.30
BIYA
+11.30%
$0.28
AGNC
+1.53%
$10.56
BAC
+0.97%
$52.99
CLSK
+14.57%
$15.41
TWOH
0.00%
$0.00
INHD
-1.55%
$0.22
WLGS
-5.57%
$0.04
BMNR
+6.26%
$33.72
MTSR
-0.35%
$70.50
SNAP
+0.14%
$7.62
ONMD
+45.07%
$2.06
TSLA
+0.55%
$428.96
PCG
+1.78%
$16.01
CIFR
+10.05%
$21.07
PLUG
+2.09%
$2.02
AFMD
-34.94%
$0.18
ADTX
+18.78%
$3.72
MARA
+5.02%
$11.66
GPUS
-6.69%
$0.31
NVTS
+3.86%
$8.34
DEFT
+11.51%
$1.55
NIO
+0.36%
$5.48
KWM
+12.77%
$0.74
CHR
-4.18%
$0.04
BMNU
+14.89%
$8.64
F
+0.68%
$13.28
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
AMCR
+1.29%
$8.62
ONDS
-2.81%
$8.00
TEVA
+5.32%
$26.32
GOOGL
-0.60%
$318.02
SOFI
+3.18%
$29.39
VALE
+0.31%
$12.54
BTG
+3.37%
$4.62
CRCL
+11.05%
$80.67
KDLY
+7.20%
$0.49
AAL
+0.60%
$14.01
DVLT
-6.33%
$1.99
SMX
+222.58%
$56.13
CSCO
-0.32%
$76.07
IBRX
+11.50%
$2.37
CAN
+12.59%
$1.03
WULF
+5.18%
$15.61
IREN
-0.44%
$48.23
BTBT
+2.58%
$2.38
BURU
+5.44%
$0.23
SAND
-6.04%
$12.12
RIOT
+9.45%
$16.37
NGD
+5.86%
$8.30
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
APLD
+7.21%
$26.74
GRAB
+2.67%
$5.46
AG
+12.27%
$15.16
GOOG
-0.73%
$317.92
AMD
+0.97%
$216.32
CRCG
+21.27%
$2.85
KO
+0.37%
$72.88
C
+1.31%
$102.50
CRCA
+22.96%
$4.52
ABVE
+16.17%
$3.05
NEHC
+8.33%
$5.07
RIVN
+4.57%
$16.92
COMP
-0.76%
$10.42
CDE
+6.02%
$17.16
ACHR
+4.07%
$7.79
RF
+0.11%
$25.45
KEY
+0.16%
$18.40
MSTR
+2.73%
$180.44
DNN
+1.09%
$2.58
ZIM
+0.97%
$19.70
ORCL
-1.88%
$201.09
BTE
+2.68%
$3.24
AMC
+6.95%
$2.46
HL
+4.61%
$16.70
PLTR
+0.77%
$167.05
AMZN
+1.25%
$232.04
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.